A new study shows that nonmyeloablative, related haploidentical blood stem cell transplants can help eliminate the disease in older patients up to 75 years of age. Researchers found similar benefits among participants in their 50s, 60s and 70s, suggesting that age is not a barrier to successful outcomes after half-matched transplant. "These results underscore that a reduced-intensity, related haploidentical transplant should be considered a very reasonable treatment option for suitable patients up to at least age 75 who require a transplant," said lead researcher Dr. Yvette Kasamon of the Johns Hopkins Kimmel Cancer Center.

Full Story:

Related Summaries